FDA Rejection Sparks Major Securities Lawsuit Against Corcept Therapeutics
Corcept Therapeutics Incorporated ($CORT) is now the target of a securities fraud class action lawsuit alleging the company misrepresented clinical trial data supporting its lead drug candidate, relacorilant, in communications with the FDA. The legal action centers on claims that Corcept made false and misleading statements about the strength of clinical evidence backing the drug's New Drug Application (NDA), ultimately causing significant shareholder losses when the FDA rejected the application and the stock price collapsed.
On December 31, 2025, the FDA issued a Complete Response Letter (CRL) denying approval for relacorilant, marking a major setback for the biopharmaceutical company. This regulatory rejection triggered an immediate and severe market reaction: $CORT's stock price plummeted 50.4%, erasing billions in market capitalization and devastating investor portfolios. The timing and magnitude of the price decline have prompted legal action from affected shareholders, with law firm Kirby McInerney LLP representing the class and establishing an April 21, 2026 deadline for investors to join the lawsuit as lead plaintiffs.
The Clinical Data Controversy
At the heart of the securities fraud allegation lies a fundamental disconnect between Corcept's public statements and the FDA's private concerns. According to the lawsuit, the company had characterized relacorilant as "approaching approval" in investor communications and regulatory filings during the period between October 31, 2024 and December 30, 2025—the class period that defines eligible investors.
However, the lawsuit contends that the FDA had raised repeated and substantial concerns about the adequacy of clinical evidence supporting the drug's safety and efficacy profile. These regulatory red flags apparently contradicted the company's optimistic public messaging about approval prospects. The Complete Response Letter represents an explicit rejection of the company's data package, suggesting the FDA's underlying concerns were serious enough to warrant outright denial rather than a request for additional data.
The lawsuit highlights several critical facts:
- FDA repeatedly signaled concerns about clinical evidence strength prior to the final rejection
- Company made "approaching approval" statements despite knowing of FDA reservations
- Complete Response Letter issued December 31, 2025, denying the NDA entirely
- Stock price fell 50.4% immediately following the regulatory decision
- Class period runs October 31, 2024 through December 30, 2025—approximately 14 months
Market Context and Industry Implications
The Corcept situation reflects broader challenges in the specialty pharmaceutical sector, where clinical development timelines remain unpredictable and regulatory approval is never certain, despite company optimism. Corcept's relacorilant was intended to treat Cushing's syndrome, a rare but serious endocrine disorder, positioning the company to capture a niche but potentially lucrative market segment.
The FDA's Complete Response Letter mechanism, while less severe than an outright rejection of an application, still represents a significant regulatory setback. Companies typically receive CRLs when the FDA determines that additional clinical data, manufacturing information, or other information is necessary before approval can be granted. The fact that Corcept received one—rather than a Request for Additional Information—suggests substantial deficiencies in the submitted data package.
This case also underscores the importance of regulatory transparency and careful claims management in the biotechnology sector. Investor communications about late-stage clinical development and FDA interactions are scrutinized closely, particularly when stock prices are sensitive to regulatory outcomes. The alleged discrepancy between Corcept's public optimism and the FDA's documented concerns represents exactly the type of information asymmetry that securities fraud claims are designed to address.
Investor Implications and Legal Timeline
For $CORT shareholders, the implications are twofold: immediate capital losses and the potential for partial recovery through the class action settlement process. Investors who purchased Corcept securities between October 31, 2024 and December 30, 2025 are eligible to participate in the lawsuit. This encompasses individuals who acquired stock at any price point during this 14-month window, regardless of whether they still hold the shares.
The April 21, 2026 deadline to become lead plaintiff is a critical date for investors seeking to take an active role in the litigation. Lead plaintiffs typically receive enhanced recoveries and have input into settlement negotiations. However, all class members—not just lead plaintiffs—will benefit from any eventual recovery, though administrative costs and attorney fees will reduce the total payout.
The lawsuit process in securities fraud cases typically involves several stages:
- Class certification determining which investors qualify for recovery
- Discovery phase where both parties exchange evidence regarding company knowledge and intent
- Settlement negotiations or potentially trial (though most settle)
- Recovery distribution to eligible shareholders with documented losses
Historically, securities fraud settlements in the pharmaceutical sector have recovered 30-50% of documented losses, depending on the strength of evidence and the defendant's financial resources. Corcept's financial position will influence both the company's settlement capacity and its willingness to litigate versus settle.
Looking Forward
The rejection of relacorilant represents a critical inflection point for Corcept Therapeutics. The company now faces the dual challenge of restructuring its pipeline and managing significant legal liability. Whether the FDA's concerns about relacorilant can be addressed through additional clinical work remains to be seen, but the Complete Response Letter suggests fundamental questions about the drug's efficacy or safety profile that are not easily resolved.
For the broader biotech sector, the Corcept case serves as a reminder that regulatory optimism—even when apparently justified based on prior interactions—can quickly evaporate when the FDA issues its formal determination. Companies communicating with investors about regulatory timelines must maintain rigorous documentation of FDA feedback and avoid characterizing approval as imminent without explicit regulatory guidance supporting that view.
Investors holding $CORT shares or those who purchased during the class period should carefully review their transaction records and consider consulting with securities counsel about their eligibility to recover losses through the class action mechanism. The April 21, 2026 deadline represents a hard cutoff for joining as lead plaintiff, after which investors can still participate in the class but lose any leadership role in the litigation.